Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” - Yoon-Koo Kang; Hyung-Don Kim; Min-Hee Ryu (Journal for ImmunoTherapy of Cancer)